Exelixis, Inc. Profile Avatar - Palmy Investing

Exelixis, Inc.

Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients…

Biotechnology
US, Alameda [HQ]
US · Macroeconomic Factors/Risks · Forecasts

Macro

Exelixis, Inc. mainly operates in US (Alpha-2: US, Alpha-3: USA)

United States
Analysis Results
B Overall Rating
19 Analyzed Indicators
B Annual Indicators Rating
16 Analyzed Indicators
B+ Monthly Indicators Rating
3 Analyzed Indicators
Likelihood Legend A++ is best, F- worst
  • A++
  • A+
  • A

  • Very Unlikely
  • B+
  • B

  • Unlikely
  • C+
  • C
  • D+
  • D
  • D-

  • Avg.
  • E+
  • E-

  • Unlikely
  • F+
  • F
  • F-

  • Very Unlikely
Indicator

All indicators comes from high quality sources, such as the world bank, OECD, FRED and manuel datasets such as Premiums by Prof. Damodaran.

Rating
End of EXEL's Analysis
CIK: 939767 CUSIP: 30161Q104 ISIN: US30161Q1040 LEI: - UEI: -
Secondary Listings
EXEL has no secondary listings inside our databases.